- Results from the Phase 4 ASCENT study showed AstraZeneca's (NYSE:AZN) Tudorza Pressair (aclidinium bromide) 400 μg, administered twice daily as background therapy, produced a statistically significant reduction on the annual rate of moderate or severe exacerbations compared to placebo in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) with significant cardiovascular risk factors.
- The study also met the primary safety endpoint.
- The company is continuing its analysis of the data. Complete results will be shared with the FDA and submitted for presentation at a future medical conference. It also plans to file a U.S. marketing application for the expanded indication of Tudorza.
- AstraZeneca is collaborating with Circassia Pharmaceuticals on the development and commercialization of Tudorza and Duaklir (aclidinium bromide/formoterol) in the U.S.
- Now read: Week In Review: Walgreens Boots Alliance (NASDAQ:WBA) Spends 0 Million For China Pharmacy Presence
Original article